Sunstone Life Science Fund II portfolio company Orpahzyme, announces its intention to launch an Initial Public Offering (“IPO” or “Offering”) of its shares and to apply for admission to trading and official listing on Nasdaq Copenhagen. The intended IPO is expected to consist of an issue of new shares to raise gross proceeds of approximately DKK 600 million to support the Company’s strategy by primarily funding on-going and planned clinical trials within four orphan diseases. The total offer size will be announced in connection with the publication of a prospectus by the Company.
For full text of the announcement, please refer to www.orphazyme.com
Starting immediately, Arcoma will be selling Arcoma branded systems integrated with Canon image software and detectors throughout Europe, the Middle East and Africa.
Until now, Canon distributors have bought the image software and the detectors directly from Canon Europe, having two points of sourcing for a complete system. This new agreement allows Arcoma to deliver the completely integrated system, ensuring functionality, quality and reducing installation time for its customers. The agreement will increase Arcoma sales by approx. 25 MSEK per year and will strengthen the Arcoma brand in Europe considerably.
“We are proud to be able to sell the complete Arcoma branded systems with the Canon detectors throughout EMEA. The strengthened alliance with Canon allows us to pre-stage systems prior to installation, thus reducing installation time for end-users and ensuring system functionality and quality. This is further an important part of Arcoma’s strategy to strengthen the Arcoma brand and increase its product offering”, says CEO Mikael Högberg.
Life Science Ventures Fund II portfolio Company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that preclinical data with its oral T-cell immunotherapy platform, including one preclinical development candidate, VXM10, are being presented at the upcoming “AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications” being held October 26-30, 2017 in Philadelphia, PA, USA. The poster will be presented during Poster Session B in session category “Tumor Immunology Targets” on Sunday October 29, 12:30 PM – 4:00 PM in Hall E.
Sunstone Life Science Fund II portfolion Company CMC Contrast AB acquires Oncoral Pharma Aps to further strengthen its product portfolio within oncology. In connection with the acquisition, the company is re-named to Ascelia Pharma AB.
“Through the acquisition, Ascelia Pharma is truly established as a pioneer in developing novel medicinal products to address unmet medical needs for people living with cancer. The acquisition of Oncoral broadens our oncology product portfolio and fits well with our existing lead drug candidate MangoralTM. With Oncoral, we now have two clinical stage medicinal product candidates in our pipeline and both candidates have the potential to become global leaders in their indications as they will have significant advantages compared to currently available products”, says Magnus Corfitzen, Chief Executive Officer of Ascelia Pharma.
Sunstone Life Science Fund II portfolio company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company’s lead product candidate, VXM01, has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioma, a difficult-to-treat form of brain cancer. Orphan designation is designed to encourage the development of drugs to treat rare diseases and conditions and provides companies with certain incentives, including periods of market exclusivity upon approval, as well as user fee reductions or exemptions. The designation by the European Commission is for the treatment of glioma and by the US FDA for the treatment of malignant glioma.